381 related articles for article (PubMed ID: 36866388)
21. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
Kudo M; Galle PR; Brandi G; Kang YK; Yen CJ; Finn RS; Llovet JM; Assenat E; Merle P; Chan SL; Palmer DH; Ikeda M; Yamashita T; Vogel A; Huang YH; Abada PB; Yoshikawa R; Shinozaki K; Wang C; Widau RC; Zhu AX
JHEP Rep; 2021 Apr; 3(2):100215. PubMed ID: 33392490
[TBL] [Abstract][Full Text] [Related]
22. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
[TBL] [Abstract][Full Text] [Related]
23. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
24. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2022 Oct; 16(5):1150-1160. PubMed ID: 35749019
[TBL] [Abstract][Full Text] [Related]
26. Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
Yang Z; Suda G; Maehara O; Ohara M; Yoda T; Sasaki T; Kohya R; Yoshida S; Hosoda S; Tokuchi Y; Kitagataya T; Suzuki K; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Ogawa K; Ohnishi S; Sakamoto N
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765554
[TBL] [Abstract][Full Text] [Related]
27. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
28. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
[TBL] [Abstract][Full Text] [Related]
29. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Personeni N; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
Liver Int; 2022 Nov; 42(11):2538-2547. PubMed ID: 35986902
[TBL] [Abstract][Full Text] [Related]
30. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
[TBL] [Abstract][Full Text] [Related]
31. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX; Abbas AR; de Galarreta MR; Guan Y; Lu S; Koeppen H; Zhang W; Hsu CH; He AR; Ryoo BY; Yau T; Kaseb AO; Burgoyne AM; Dayyani F; Spahn J; Verret W; Finn RS; Toh HC; Lujambio A; Wang Y
Nat Med; 2022 Aug; 28(8):1599-1611. PubMed ID: 35739268
[TBL] [Abstract][Full Text] [Related]
32. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
33. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
[TBL] [Abstract][Full Text] [Related]
34. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
[TBL] [Abstract][Full Text] [Related]
35. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Wu YL; Fulgenzi CAM; D'Alessio A; Cheon J; Nishida N; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ; Ang C
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497316
[TBL] [Abstract][Full Text] [Related]
37. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
[TBL] [Abstract][Full Text] [Related]
38. Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Takada H; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Muraoka M; Suzuki Y; Sato M; Kobayashi S; Yoshida T; Takano S; Maekawa S; Enomoto N
Oncology; 2023; 101(10):655-663. PubMed ID: 37379802
[TBL] [Abstract][Full Text] [Related]
39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
